This paper proposes a novel complementary approach to evaluate the public health benefits of air pollution control, where the joint impact on individuals' quality and length of life is fully quantified using Markov modelling. A Markov model which captures, for the first time: (i) air pollution's influence on population individuals' quality of life and life expectancy at baseline and (ii) dynamics in individuals' susceptibility to air pollution exposure, is developed. In order to represent the body of epidemiological evidence on the cardio-respiratory effects of long-term exposure to fine particulate air pollution, the model is structured around three diseases: chronic obstructive pulmonary disease, coronary heart disease and lung cancer. Application of the model provides the first estimates of age and gender-specific quality-adjusted life years (QALY) gains from air quality improvement in the UK. Reducing mean P M 2.5 concentrations by 1µg/m 3 in London and in England and Wales is expected to yield more than 63,000 and 540,000 QALYs respectively, to adults aged 40 and above over their remaining lifetime, discounting at 3.5% p.a. At a WTP value for a QALY of £65,000, which is in line with recommendations for the UK, the expected discounted monetary benefit of the intervention amounts to £4 billion in London and £34 billion in England and Wales.
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Introduction
In recent years, as the body of evidence on the adverse health effects of air pollution has kept on growing, policy-makers have been increasingly under 5 pressure to take action but also, to ensure that further air quality efforts are worthwhile (HEI, 2003) . This has spurred several ex ante economic evaluations of large-scale regulatory interventions of air pollution control (e.g. Revisions to the National Ambient Air Quality Standards for Particulate Matter in the US (US EPA, 2012), Clear Air for Europe (Holland et al., 2005) , revisions of 10 the E.U. Gothenburg Protocol (Holland et al., 2011) ) and of a large number of hypothetical scenarios of air pollution reduction on a local, national or global scale (Bell et al., 2011) .
The mortality effects of reducing air pollution are traditionally quantified in premature deaths avoided or life expectancy gains using life-tables, whereas 15 morbidity impacts are measured in counts of avoided morbid cases obtained by health impact functions (Medina et al., 2013) . In addition to being quantified with a static quantification tool, the morbidity effects considered are primarily acute (e.g. hospitalizations, respiratory exacerbations) following short-term variations in air pollution exposure (WHO, 2013) . Consequently, the long-term 20 quality of life impacts associated with a reduction in chronic morbidity following a sustained decrement in ambient levels of air pollution, have largely been ignored. This paper therefore proposes a novel complementary approach to evaluate the public health benefits from air pollution control, where the joint impact on 25 individuals' quality and length of life, measured in quality-adjusted life years (QALYs), is fully quantified using Markov modelling.
The QALY combines morbidity and mortality effects into a single index and is obtained by multiplying the period of time spent in a given health state by health-related quality of life (HRQoL) weights associated with that state (Gold 30 et al., 2002) . The benefits of using this metric in environmental health policy include the ability to compare health outcomes from different policies, to consider another dimension than quantity of life and to encompass individuals' preferences between alternative health states (Ponce et al., 2001 ). In addition, since the QALY routinely supports health care resources allocation (Drummond et al., 35 2005), its use in the assessment of air pollution control interventions can support the comparison with health care interventions, for which cost-effectiveness decision rules are typically in place.
Whilst there have been a number of attempts to estimate the QALY gain from air pollution reduction, they all suffer from two main limitations. To 40 put them into context, it should be noted that air pollution can affect individuals' health via three main pathways to effect: (A) development of chronic conditions that reduce life expectancy and quality of life but are unrelated to the timing of death; (B) death advancement, following acute exposure, in frail individuals whose frailty is unrelated to air pollution exposure; and (C) develop-45 ment of chronic conditions leading to frailty combined with death advancement following acute exposure (Künzli et al., 2001) . Correct quantification of the QALY impacts of air pollution exposure requires to jointly consider these three pathways to effect, in particular to avoid under-estimating the life expectancy and quality of life loss associated with the premature deaths of individuals in 50 pathway C (Hubbell, 2006) . This challenging issue, however, has not yet been adequately addressed. Using the life-table method, Coyle et al. (2003) simply applied HRQoL weights for the general population to the life year gains from a lower risk of premature mortality and completely ignored the quality of life gains associated with reduced morbidity. Cohen et al. (2003) used a similar method 55 but assumed that all the individuals who die prematurely from air pollution suffered from a preexisting coronary or respiratory condition, without accounting for air pollution's role in driving a subset of them to such health state. Such an 3 approach further contributed to underestimating the QALY gain of air pollution control. Whilst Hubbell (2006) partly accounted for air pollution's impact 60 on quality of life via the development of chronic bronchitis, he did not use the resulting level of quality of life as a baseline to adjust the life years gains from a reduced mortality risk. This use of a double baseline of HRQoL weights to assess respectively morbidity and mortality effects -an approach also used by the US EPA (US EPA, 2006) to estimate MILYs -no longer allows a linear 65 substitution between quality and quantity of life and thus, clearly departs from the QALY.
Second, none of the above-mentioned studies accounted for the fact that individuals suffering from a compromised health condition are expected to be more susceptible to air pollution exposure than healthier individuals (Peled, 70 2011; Sacks et al., 2011; US EPA, 2009 ). Health-related heterogeneity in susceptibility to air pollution drives the distribution of impacts among population subgroups stratified by health condition. It is therefore key to accurately adjust life expectancy effects with HRQoL weights.
In contrast, by simulating individuals' health trajectories over time to and 75 from a set of mutually exclusive and exhaustive health states, the proposed Markov modelling-based approach provides two core advantages to estimate the QALY gain from air pollution abatement. First, individuals' quality of life and life expectancies are no longer treated as exogenous parameters. Instead, they are endogenously determined as a function of individuals' current health con-80 ditions, where the influence of air pollution in driving them to their respective states of health is fully accounted for. Second, individuals' change in susceptibility to air pollution exposure over time, as a consequence of a degraded health condition that may or may not be associated with air pollution exposure, is encompassed. Thanks to these two features, the lifetime impact of chronic air 85 pollution exposure on individuals' quality and length of life is fully captured.
In addition, the proposed approach can quantify both the health care savings from a reduced occurrence of morbidity events, as well as the health care costs from extending the lives of individuals with chronic medical conditions. As a 4 consequence, the total health care budget impact of reducing air pollution can 
Materials and methods

Scope of analysis
105
The present analysis aims to quantify the lifetime impacts on life expectancy, quality of life and health care resources of reducing population exposure to P M 2.5 , i.e. particulate matter smaller than 2.5µm in aerodynamic diameter, which is considered to adversely affect population health more than any other air pollutant (WHO, 2014) .
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Given the chosen timescale, only chronic health effects from long-term exposure are modelled. Consequently, short-term quality of life effects from morbid events triggered by acute exposure, such as respiratory exacerbations for instance, are not presently taken into account 1 . The latter are, however, not expected to drive levels of quality of life over a lifetime.
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1 It should be noted that the life-shortening effect of acute exposure is captured in the overall change in death risk associated with chronic exposure (Künzli et al., 2001 ).
5
Although children are expected to be particularly susceptible to air pollution (Peled, 2011) , documented adverse effects primarily pertain to respiratory exacerbations following acute exposure, which are outside the present scope of analysis, or to subclinical respiratory conditions (e.g. reduced lung growth) which are not well characterised with incidence and prevalence statistics. On 120 these grounds, the present analysis focuses on chronic health impacts experienced in adulthood. Importantly, since chronic respiratory impacts in adults partly derive from the worsening over time of subclinical conditions developed since childhood (Eisner et al., 2010; Peled, 2011) , the long-term damaging impact of chronic P M 2.5 exposure on children's lung development should to some 125 extent, be encompassed in the analysis.
Main chronic health impacts in adults
130
As explained in section 1, the life shortening impact of particulate air pollution exposure is expected to be greatly mediated via the increase in the risks of developing chronic conditions. Epidemiological studies suggest a positive association between long-term exposure to fine particulate air pollution and coronary atherosclerosis (Adar et al., 2013) , myocardial infarction (Lipsett et al., 2011), 135 coronary re-vascularization (Miller et al., 2007) and acute and sub-acute forms of coronary heart disease (Cesaroni et al., 2014) . Whilst particulate matter (PM) exposure has also been associated with stroke (Miller et al., 2007) , to date the overall evidence of association with regards to long-term exposure remains weak (Brook et al., 2010) . Based on this body of evidence and constraints in terms of 140 required population statistics, the impacts of chronic air pollution exposure on the cardiovascular system were modelled using coronary heart disease (CHD) -ICD-10 I20-I25 -as health endpoint.
A number of studies have also shown positive associations between PM exposure and respiratory symptoms (Schindler et al., 2009; Abbey et al., 1995) as
well as lung function decrements (Downs et al., 2007) , all of which are associated with chronic obstructive pulmonary disease (COPD). Although the body of evidence linking PM exposure and COPD development remains incomplete (Schikowski et al., 2013) , such association is likely as reduced pulmonary growth in childhood and adolescence -for which the link with PM exposure is now es-150 tablished -increases the incidence of COPD later in life (Eisner et al., 2010) .
The COPD disease pathway (ICD-10 J40-J44) was therefore chosen to model the chronic respiratory impacts of PM exposure.
Lung cancer (ICD-C33-34), which has repeatedly been found to be associated with chronic PM exposure (Hamra et al., 2014) , was considered as a third 155 morbidity endpoint.
2.3. Model structure 2.3.1. Markov models: key features
160
Discrete time Markov models are extensively described in Sonnerberg and Beck (1993) . They have two key structural components: (i) mutually exclusive and exhaustive health states and (ii) transition probabilities (TP) which represent the probability of transiting between health states during a cycle "c",
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conditional on being in a given health state in cycle "c-1". TP can, however, be conditional on past health history using tunnel states in which individuals can only spend one cycle. TP are typically stratified by age and gender and are time-dependent. 
Disease pathways
The model was built around three disease pathways -one for each chronic morbid condition defined in section 2.2 -alongside the states "dead" and "healthy", where the latter represents a health state exempt of any of the three conditions.
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As the analysis timescale was the individual's lifetime, the cycle period was set to one year. Due to data gaps pertaining to co-morbidity risks, the model assumed competitive risk between the three diseases, i.e. one individual cannot suffer from two or more conditions at the same time. In addition, each disease pathway was underpinned by the following structural assumptions:
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COPD. As health care cost, quality of life decrements and mortality risk greatly depend on the level of airflow obstruction, the COPD pathway was structured around the four severity stages: GOLD 1 to GOLD 4, defined by the Global initiative for chronic Obstructive Lung Disease (GOLD, 2014). Although COPD is treatable, it is not reversible and typically slowly worsens over time. In addition,
185
it is often diagnosed in late stages (GOLD, 2014) . To reflect these characteristics, the COPD pathway was designed as unidirectional -i.e. transitions back to "healthy" or to a less severe state were not permitted -and upon entry into the disease pathway, no jump of severity stage was allowed. By contrast, to reflect the reality of late diagnosis, transitions from the state "healthy" to the 190 first three severity levels of the disease were allowed (see Figure 1 ).
CHD.
Although CHD also has different levels of severity that will influence quality of life and life expectancy, in the absence of a widely accepted classification of the disease by severity stages, the CHD pathway was composed of only one state. The CHD pathway was also designed as unidirectional, since CHD is 195 a chronic condition that requires long-lasting disease management.
Lung cancer. Whilst 5-year lung cancer survivors remain at risk of cancer recurrence, most recurrences (around 80%) occur about 2 years after surgical resection (Maeda et al., 2010) . Consequently, it was assumed that after 5 years alive with the condition, individuals would transit back to the state "healthy", 200 from where they would face the same risks of adverse health events and enjoy the same quality of life as "healthy" individuals of same age and gender. The disease pathway was structured around five tunnel states, in order to differenti-8 ate lung cancer patients and their survival probabilities according to the period of time during which they had been suffering from the disease. 
Intervention arm and risk reduction estimates
To evaluate an intervention of air pollution reduction, the model requires:
a "baseline" arm populated with baseline TP and (ii) an "intervention" arm 210 in which baseline TP are combined with risk reduction estimates (RRE). The latter are epidemiological risk estimates scaled to the decrement in exposure associated with the intervention under evaluation.
In addition to morbidity RRE that represent the decrease in the risks of developing lung cancer, CHD and COPD, mortality RRE were applied in the
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"intervention" arm so that the total life expectancy gain from air pollution reduction, mediated by the three pathways to effect described in section 1, would be captured.
In line with WHO (2013)'s recommendations, mortality RRE pertaining to all causes of death were used. The specificity of the present model, however, 220 is that it relies on mortality RRE stratified by health status, i.e. conditional on having CHD or COPD or LC or on being "healthy". Such an approach is key to: (i) capture health-related differential susceptibility to air pollution, by allowing for a different magnitude of death risk reduction according to whether individuals are frail or not; and (ii) avoid double-counting the life expectancy 225 gains from the reduced risk of developing a chronic cardio-respiratory condition, which are already encompassed via the application of morbidity RRE in the model. It follows that the change in death risk that was applied to "healthy" individuals pertains to all the other causes of death than the three modelled.
The change in death risk in individuals who had developed COPD and CHD,
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be it due to air pollution exposure or for any other reasons, was informed by Zanobetti et al. (2008) and Tonne and Wilkinson (2013) 's respective estimates of excess risk of all-cause mortality associated with chronic PM exposure in 9 these two populations subgroups. Zanobetti et al. (2008) results, however, were based on COPD patients who were aged above 65 years old and had been 235 identified using hospital discharge data. As the risk of hospital admission for COPD greatly increases with disease severity, in order to limit study results extrapolation, the study's risk estimate was applied only to individuals aged 65
and above if they were in GOLD 3 or 4 states. Individuals with COPD in GOLD stages 1 and 2 or, in GOLD stages 3 and 4 but aged below 65, were instead 240 assumed to face the same reduction in mortality risk as the general population.
Similarly, Tonne and Wilkinson (2013)'s study was based on patients above 25 years of age admitted to hospital following acute coronary syndrome (ACS).
ACS reflects a more severe health condition than CHD as a whole. Since the risk of ACS strongly increases with age (Simms et al., 2012) , Tonne and Wilkinson 245 (2013)'s risk estimate was applied to individuals suffering from CHD only if they were aged 75 or above. Individuals with CHD aged below 75 were assumed to face the same reduction in mortality risk as the general population.
Finally, since lung cancer is associated with a high risk of death, the impact of P M 2.5 exposure was restricted to disease development (RRE c ). In other 250 words, reducing air pollution was assumed to have no impact on the mortality risk of individuals with lung cancer.
RRE and the TP they apply to are presented in Table 1 . Risk estimates were preferably taken from meta-analyses to decrease parameter uncertainty.
They were obtained from studies undertaken in developed countries that are 255 characterised by P M 2.5 concentrations ranging from about 7 to 35 µg/m 3 , for which linearity in health impacts and absence of threshold to effects has typically been found (Lepeule et al., 2012; Crouse et al., 2012; Krewski et al., 2009 is assumed to be unchanged under intervention. Abbreviations: P X,Y : age and gender-specific annual probability of developing disease/ experiencing event "Y", conditional on being in health state "X"; Dev. = developing; COPD = chronic obstructive pulmonary disease; CHD = coronary heart disease; LC = lung cancer; H = healthy; D = dead; HR = hazard ratio; HR Y |X : hazard ratio of event "Y" in population with health condition "X"; OR = odd ratio; AC = all causes; AOC = all other causes than COPD, CHD and LC.
(a) As TP are non-linear function of time, their multiplication with RRE is carried out on the transition rate scale. The obtained product is then converted back to probability to parameterise the intervention arm.
(b) Meta-analysis study. The lag between exposure decrement and health risks reduction was assumed to follow the 20-year distributed lag developed and currently used by the US EPA: 30% risk reduction in year 1, an additional 12.5% every year between year 295 2 to year 5 and the final 20% being phased in gradually over year 6 to year 20 (US EPA, 2010). However, since the US EPA's lag was developed to evaluate the change in the risk of all-cause mortality, sensitivity analysis using different lags for morbid endpoints will be performed. For comparability with health care interventions, a discount rate of 3.5% was applied to health care costs and 300 QALY gains, in line with guidelines for England and Wales (NICE, 2013). Parametrisation of the COPD pathway was slightly more complex, owing to the need to account for disease progression at patient-level as well as severe under-diagnosis of the disease, whereby less than a third of individuals with probable airflow limitation reported a doctor-diagnosis of COPD in 2010
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Health Survey for England (Aresu et al., 2011) . COPD progression probabilities were derived by combining annual progression probabilities stratified by smoking status provided by Atsou et al. (2011) with data on the distribution of COPD patients in England by smoking status from Shahab et al. (2006) . This approach was justified by the lack of strong evidence to date that suggests 330 that smoking could impact upon individuals' biological response to air pollution exposure (Laurent et al., 2007) . Death probabilities associated to the COPD pathway were calculated using GOLD-stratified hazard ratios of excess mortality in COPD patients estimated by Mannino et al. (2006) . The incidence of the disease by severity stage was estimated by combining disease progression 
HRQoL weights
350
The EuroQol five dimensional instrument (EQ-5D), which is the most commonly used HRQoL metric for cost-effectiveness analysis (De Smedt et al., 2014) was chosen to express the quality of life associated with each health state.
Age and gender-specific HRQoL scores experienced by "healthy" individuals 355 were obtained from Kind et al. (1999) . HRQoL scores associated with each condition are presented in Table 2 (left-hand side). HRQoL weights applied to each condition were upper-bounded by the age and gender-matched scores of "healthy" individuals. Scores for COPD (by GOLD stages) and lung cancer were taken from meta-analyses (Pickard et al., 2008; Sturza, 2010) and CHD
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scores were based on a very large patient population size (n=7,242) as part of the EUROASPIRE III study (De Smedt et al., 2014) .
The HRQoL score for lung cancer was based on results for non-small cell cancer, which accounts for about 90% of all cases of cancer in England (Riaz et al., 2012) . The final HRQoL score was obtained by weighting HRQoL results
365
for metastatic and non-metastatic non-small cell cancer by respectively 75% and 25%, based on the fact that 75% of non-small cell cancers are detected at an advanced stage (NHSC, 2010) .
Health care costs
370
"Healthy" individuals were assumed not to generate any health care cost.
The average annual health care cost per patient in each condition is provided in Table 2 (right-hand side). Costs were inflated to 2013 prices, based on the hospital and community services' inflation index for the UK NHS (PSSRU, 375 2013).
In the absence of UK specific data, COPD costs stratified by GOLD stage were based on a Swedish study (Jansson et al., 2013) . (a) Converted in GBP using the average EUR/GBP exchange rate for 2013.
Sensitivity analyses 390
Joint-uncertainty in a subset of parameters was handled probabilistically by fitting lognormal distributions to risk estimates and beta distributions to HRQoL scores (Briggs et al., 2006) and by performing Monte Carlo simulations (10,000 draws). In addition, the sensitivity of results to discount rate and to 395 lags in risk reduction was evaluated. 17
Summary of assumptions
In order to point out potential biases associated with the model and its application to the UK case study, a list of the main assumptions/limitations is 400 provided in Table 3 .
Limitations expected to led to a moderate under-estimation of impacts
Case study:
-The target population is a static adult population aged 40 and above Nature of effects captured in the model:
-Adverse effects in children are not encompassed (a)
-Quality of life effects from acute exposure are not captured
Model structure:
-Competitive risks between each three diseases is assumed
Limitations for which the direction of the potential bias is unclear
Model parameterisation:
-All-cause mortality RRE applied to individuals with CHD or COPD are based on single study results, as opposed to meta-analyses -For individuals with CHD or COPD, the use of all-cause mortality RRE does not exactly match with the baseline probability of death of these individuals, because of the competitive risk assumption (c) -Correct estimation of the total life expectancy gain from air pollution reduction requires valid baseline: (i) incidence of the three life-shortening conditions modelled (b) and (ii) death risks stratified by health status Table 3 : Model limitations and expected direction of potential biases.
(a) Air pollution deleterious effects on children lung development are nevertheless expected to be partially encompassed in the excess risk of developing COPD in adulthood.
(b) This prompted the estimation of the "true" underlying incidence of COPD, in order to address the fact that this disease is severely under-diagnosed (see section 2.4.3) (c) This is not an issue for "healthy" individuals or for those with lung cancer since the change in death risk that was applied to "healthy" individuals pertains to all the other causes of death than the three modelled and for those with lung cancer, no PM-related excess death risk was applied.
Results
3.1. Total QALY gain, health care resource impact and monetary benefit of in-
405
tervention Detailed summary results are provided in Table 4 . Reducing mean P M 2.5
concentrations by 1µg/m 3 is expected to generate more than 63,000 QALYs in London and 540,000 QALYs in England and Wales, among adults currently 410 aged 40 and above over their remaining lifetime, discounting at 3.5% p.a.
The total net health care resource impact of the intervention, which corresponds to the health care savings from a reduction in cases of CHD, COPD and lung cancer, net of the health care costs from extending the lives of individuals with a chronic cardio-respiratory condition 4 , is slightly cost increasing. It ac-
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counts for respectively £24 million in London and £263 million in England and
Wales.
In England, health care costs to the National Health Service can be expressed as QALY losses using an estimate of the NHS expenditure required to deliver one QALY. The latter was recently estimated at £13,000/QALY (Claxton et al., 420 2013). Based on this estimate, the QALY loss equivalent from net health care costs accounts for 2.8% and 3.7% of the health benefits expected to be generated by the intervention in London and in England and Wales respectively.
If the intervention is expected to be funded by raising new tax revenue, it will displace private consumption and consequently, the population health 425 benefits it generates should be monetized based on the consumption value of a QALY. The UK Department of Health recommends to use a willingness to pay (WTP) value of a QALY of £60,000 in 2009 prices (Glover and Henderson, 2010) . In addition, Ryen and Svensson (2014) (a) Currently alive adults aged 40 to 90 years old.
(b) 60-year time horizon, applying a discount rate of 3.5 % p.a.
(c) Savings from a reduction in cases of CHD, COPD and lung cancer, net of costs from extending the lives of individuals with a chronic cardio-respiratory condition.
(d) Using a value of £13,000/QALY as the shadow price of the NHS budget constraint.
(e) Using £65,000/QALY as the consumption value of a QALY. Two scenarios of staged-discounting, based on recommendations from the UK treasury for long-term investments (Lowe, 2008) were evaluated against the base scenario, which applies a 3.5% discount rate p.a. Results are provided in Appendix D. Decreasing the discount rate to 3% p.a. after the first 30 years would lead to an increase in total net QALY gain at population level by about 490 7%, whereas applying a 3% rate p.a. in the first 30 years and a 2.57% rate p.a.
QALDays and health care costs distributions by age and gender
afterwards would boost net QALY gain by about 20%.
The sensitivity of results to cessation lag were evaluated by applying a combination of different lags to the change in health risks, namely: (i) the US EPA 20-year distributed lag (described in section 2.4.1) for the excess risk of death;
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(ii) a 5-year progressive lag for the change in the excess risks of developing CHD and COPD and (iii) a 20-year progressive lag for the change in the excess risk of developing lung cancer. Results are provided in Appendix E. This "mixed lag" was found to have a minor effect on the total net QALY gain at population level (increase by about 3%).
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5 Whilst Pascal et al. (2013) did not apply a cessation lag, the present application of the US EPA cessation lag to RRE is expected to have a relatively small effect on the health gain accruing to young individuals since 80% of the risk reduction is assumed to happen after only 5 years since decrement.
Conclusions
This study provides a novel approach to evaluating the public health benefits of air pollution control on both quality and length of life dimensions that en- in London and in England and Wales (i.e. by 7% and 9% respectively) is expected to yield more than 63,000 and 540,000 QALYs respectively, to adults aged 40 and above over their remaining lifetime when discounting at 3.5% p.a.
Against expectations, such an intervention is expected to slightly increase health care costs. Indeed, after the age of 53, the health care savings from 525 reducing the probability that individuals develop COPD, CHD or lung cancer are on average, more than compensated by the costs associated with extending the lives of those with a chronic cardiac or respiratory condition. Net health care costs, however, represent less than 4% of total health benefits, assuming the NHS delivers 1 QALY for every £13,000 it receives. At a WTP value for The model developed has, nevertheless, a number of limitations, which were outlined in Table 3 . In particular, its parameterisation is relatively complex,
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which may introduce a number of biases. It is therefore worth noting that lifeexpectancy results appear in line with previous findings in the health impact assessment literature (see section 3.3). Although air pollution's association with subclinical respiratory symptoms in children is partly captured in the increased risk of developing COPD later in adulthood, wider benefits to children, espe-550 cially to those suffering from asthma (Peled, 2011) , are not taken into account.
Furthermore, quality of life impacts from acute exposure are ignored. The model also assumes competitive risk between between disease pathways, which is a simplification of the clinical reality given that COPD is a multi-component systemic disease that is associated with a greater risk of cardiovascular events 555 and lung cancer (GOLD, 2014 may also need to be considered.
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